Vertex Pharmaceuticals (VRTX) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Vertex Pharmaceuticals (VRTX)

An SI Board Since August 1996

Posts	SubjectMarks	Bans	Symbol
1169	64	0	VRTX

Emcee: David Lieberman	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
844	GS comment: June 30, 2006 Vertex Pharmaceuticals, Inc. (VRTX) $32.03 Goldman Sa	quidditch	-	6/30/2006
843	Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Compan	caly	-	6/30/2006
842	VX-950 trial-design notes from GS webcast: tinyurl.com	DewDiligence_on_SI	-	6/18/2006
841	VX-950 milestones: PROVE-1/PROVE-2 phase-2 trials for VX-950: a) Start PROVE-2:	DewDiligence_on_SI	-	5/24/2006
840	PROVE-1 and PROVE-2, which can logically be viewed as one study in two pieces, c	DewDiligence_on_SI	-	5/23/2006
839	Vertex jumps on hepatitis C drug advancement May 23, 2006 15:47:00 (ET) BOSTO	LJM	-	5/23/2006
838	From GS dated 5/23: Vertex announced that it has initiated its anticipated broad	quidditch	-	5/23/2006
837	VX-950: the phase-2 data vs the phase-1b data: investorshub.com Today’s PR was	DewDiligence_on_SI	-	5/22/2006
836	Researchers Report Results for 28-day Phase II Study of VX-950 in Combination wi	tnsaf	-	5/22/2006
835	From GS: Additional 12-week data from a 28-day VX-950 study with alpha interfer	quidditch	-	5/22/2006
834	GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results	nigel bates	-	5/16/2006
833	Good news... Researchers Report Initial Results for 14-day Phase Ib Study of VX	kenhott	-	5/1/2006
832	Vertex May Have Removed Major Risk Factor Peter Kang, 04.12.06, 3:51 PM ET Verte	tnsaf	-	4/28/2006
831	New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Proteas	tnsaf	-	4/28/2006
830	Vertex Phase II Changes Seen As Prudent Peter Kang, 04.26.06, 12:45 PM ET Prude	tnsaf	-	4/28/2006
829	Merrill Model revised incorporating 2006 outlook We have updated our income sta	tom pope	-	4/21/2006
828	Sorry about that!..I'd not seen Miljenko's post to which Steve was refer	zeta1961	-	4/9/2006
827	It is Croatian dialect, originated in ice lend Vis, town Komiza. Even new Komiza	Miljenko Zuanic	-	4/9/2006
826	<<eloquent in Albanian (?).>> Like this? <i>Gjuha shqype Po	zeta1961	-	4/9/2006
825	I think a lot of people saw his enbrel comment and thought the same thing as Mil	rkrw	-	4/9/2006
824	MZ, having become a avid and close observer of the pecking order and the suits o	quidditch	-	4/8/2006
823	caveat emptor, or let the buyer beware, or something a bit worse but I will not	Biotech Jim	-	4/8/2006
822	Few days back JB called VX-702 "SUPER-Enbrel"! "Od boba bub, od	Miljenko Zuanic	-	4/8/2006
821	Citi: VRTX: VX-702 Well Tolerated But Not Potent BUY (1) Speculative (S)	mopgcw	-	4/8/2006
820	Very nice article.Thanks for posting... Praveen	dr.praveen	-	4/6/2006

Go to reply# or date (mm/dd/yy):